Leadership Overview
Novavax has 6 executives leading key functions including strategy, operations, human resources, legal, information technology, and medical affairs.
Driven by a commitment to global health, Novavax focuses on discovering, developing, and commercializing vaccines to combat serious infectious diseases, leveraging a proprietary technology platform for enhanced immune response and market impact.
Driven by a commitment to global health, Novavax focuses on discovering, developing, and commercializing vaccines to combat serious infectious diseases, leveraging a proprietary technology platform for enhanced immune response and market impact.
Leadership Roles at Novavax
Donald Baines - Vice President, Chief of Staff To the Chief Executive Officer
Donald Baines, the Vice President, Chief of Staff To the Chief Executive Officer at Novavax, directly supports the Chief Executive Officer's strategic initiatives and operational execution. Baines manages critical cross-functional projects, ensuring alignment between executive directives and departmental activities. This role involves facilitating communication across the organization, streamlining decision-making processes, and driving the implementation of key corporate strategies. Donald Baines also oversees the coordination of executive meetings and the preparation of essential briefing materials, ensuring the CEO is fully informed and prepared for all engagements. The focus remains on enhancing organizational efficiency and supporting the company's mission to develop and commercialize vaccines against infectious diseases.
Biegie Lee - Senior Vice President, Chief Information Officer
Biegie Lee, the Senior Vice President, Chief Information Officer at Novavax, architects and directs the company's global information technology strategy and infrastructure. Lee oversees all aspects of technology operations, including cybersecurity, data management, and digital transformation initiatives, crucial for a biotechnology firm focused on vaccine development. This leadership position ensures that Novavax's IT systems robustly support research, clinical trials, manufacturing, and commercialization efforts. Biegie Lee drives innovation in technology adoption, enhancing operational efficiency and data integrity across the organization. The CIO's mandate includes safeguarding sensitive intellectual property and patient data, while enabling seamless collaboration for Novavax's global partnerships and scientific endeavors.
Ian Watkins - Executive Vice President & Chief Human Resources Officer
Ian Watkins, the Executive Vice President & Chief Human Resources Officer at Novavax, leads all human capital strategies and organizational development initiatives. Watkins is responsible for cultivating a high-performance culture that supports Novavax's mission of developing innovative vaccines. This executive role encompasses talent acquisition, retention, compensation and benefits, employee relations, and leadership development programs designed to attract and retain top scientific and operational talent. Ian Watkins ensures that HR policies and practices align with the company's strategic objectives and regulatory requirements within the biotechnology sector. The focus is on building a diverse and engaged workforce capable of driving scientific breakthroughs and commercial success for Novavax.
Louis Fries - Chief Medical Officer
Louis Fries, the Chief Medical Officer at Novavax, directs the company's global clinical development strategy and medical affairs. Fries oversees the design, execution, and interpretation of clinical trials for Novavax's vaccine candidates, ensuring scientific rigor and adherence to global regulatory standards. This critical role involves leading teams responsible for vaccine efficacy and safety studies across various infectious diseases. Louis Fries also guides the company's engagement with the medical community, key opinion leaders, and regulatory agencies worldwide. The Chief Medical Officer's expertise is fundamental to advancing Novavax's pipeline from early-stage research through to regulatory approval and market introduction, supporting the company's commitment to public health.
Raburn Mallory - Senior Vice President, Head of Clinical Development and Deputy Chief Medical Officer
Raburn Mallory, the Senior Vice President, Head of Clinical Development and Deputy Chief Medical Officer at Novavax, collaborates closely with the Chief Medical Officer to advance the company's vaccine pipeline. Mallory spearheads the operational execution of clinical development programs, managing the day-to-day activities of clinical research teams. This involves overseeing trial site selection, patient recruitment, data collection, and ensuring compliance with Good Clinical Practice (GCP) guidelines. Raburn Mallory's leadership is essential for the timely and efficient progression of vaccine candidates through all phases of clinical testing. The role supports the strategic goals of Novavax by ensuring robust data generation that underpins regulatory submissions and demonstrates the safety and efficacy of its vaccine technologies.
Mark Casey - Executive Vice President & Chief Legal Officer
Mark Casey, the Executive Vice President & Chief Legal Officer at Novavax, provides comprehensive legal counsel and oversees all legal affairs for the company. Casey manages the legal aspects of Novavax's global operations, including intellectual property protection, corporate governance, regulatory compliance, and commercial transactions. This executive function is vital for navigating the complex legal landscape of the biotechnology and pharmaceutical industries. Mark Casey ensures that Novavax operates within all applicable laws and regulations, mitigating legal risks and safeguarding the company's assets and reputation. The Chief Legal Officer plays a key part in supporting strategic partnerships, licensing agreements, and the overall business development initiatives that drive Novavax's growth and mission.
Explore Leadership Teams in Blood & Organ Banks
OneBlood, headquartered in Orlando, Florida, is a non-profit organization that specializes in blood donation for hospitals.
Company Leadership GS
CN
VC
SP
Carter BloodCare is an independent, community blood center providing transfusion resources. Services include collection, processing, specialized laboratory testing, storage and distribution of blood and blood products. The program is accredited by the AABB, including a laboratory with accreditation for molecular testing of red cell antigens. It is licensed by the U.S. Food and Drug Administration and is a member of America's Blood Centers.
Company Leadership SP
VM
NJ
BG
Established in 1975, the Gulf Coast Regional Blood Center is headquartered in Houston, Texas. They serve more than 170 hospitals and healthcare institutions in the Texas Gulf Coast, Brazos Valley, and East Texas regions.
Company Leadership
BG
SR
DM
Emergent BioSolutions Inc., a life sciences company, provides preparedness and response solutions for accidental, deliberate, and naturally occurring public health threats in the United States. The company offers NARCAN Nasal Spray for the emergency treatment of known or suspected opioid overdose; Vaxchora vaccine for the prevention of cholera; Vivotif vaccine for oral administration for the prevention of typhoid fever; Anthrasil for the treatment of inhalational anthrax; BioThrax, an anthrax vaccine; CYFENDUS for post-exposure prophylaxis of disease following suspected or confirmed exposure to Bacillus anthracis; and Raxibacumab injection for the treatment and prophylaxis of inhalational anthrax. It also provides ACAM2000, a smallpox vaccine; CNJ-016 to address complications from smallpox vaccination; TEMBEXA for the treatment of smallpox disease caused by variola virus in adult and pediatric patients; BAT for the treatment of symptomatic botulism; Ebanga for the treatment of Ebola; Reactive Skin Decontamination Lotion Kit to remove or neutralize chemical warfare agents from the skin; Trobigard, a atropine sulfate obidoxime chloride auto-injector. In addition, the company is developing CGRD-001 for the treatment of poisoning by organophosphorus nerve agents or organophosphorus compounds; EBS-LASV to prevent Lassa fever; EBS-MARV to prevent Marburg virus disease; EBS-SUDV to prevent Sudan virus disease; Pan-Ebola mAbs for the treatment of ebola virus; SIAN Antidote for initial treatment of certain or suspected acute cyanide poisoning; UniFlu for immunity against influenza A and B viruses; and WEVEE-VLP for equine encephalitis virus infections. Further, it provides contract development and manufacturing services comprising drug substance and product manufacturing, and packaging, as well as technology transfer, process, and analytical development services. The company was incorporated in 1998 and is headquartered in Gaithersburg, Maryland.
Company Leadership MP
HA
KL
SL
Frequently Asked Questions Regarding Novavax Top Executives and Leadership Team
